NCT04227366View on ClinicalTrials.gov

Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

March 15, 2021

Study Completion Date

March 1, 2022

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

BCD-089

BCD-089 162 mg SC

BIOLOGICAL

Placebo

Placebo

DRUG

Methotrexat

15 to 25 mg/week

Trial Locations (1)

Unknown

Research Institute of Rheumotology, Moscow

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY